Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 307.05 Million KRW | 382.67% |
| 2022 | 63.61 Million KRW | -95.13% |
| 2021 | 1.3 Billion KRW | -20.58% |
| 2020 | 1.64 Billion KRW | 44.87% |
| 2019 | 1.13 Billion KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| 2011 | - KRW | 0.0% |
| 2010 | - KRW | 0.0% |
| 2009 | - KRW | 0.0% |
| 2008 | - KRW | -100.0% |
| 2007 | 40.04 Million KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - KRW | 0.0% |
| 2024 Q1 | 280.66 Million KRW | 0.0% |
| 2023 FY | 307.05 Million KRW | 382.67% |
| 2023 Q4 | 307.05 Million KRW | 31.96% |
| 2023 Q3 | 232.69 Million KRW | -17.05% |
| 2023 Q2 | 280.52 Million KRW | 236.97% |
| 2023 Q1 | 83.24 Million KRW | 30.86% |
| 2022 Q3 | 22.53 Million KRW | -45.49% |
| 2022 Q2 | 41.33 Million KRW | -45.98% |
| 2022 FY | 63.61 Million KRW | -95.13% |
| 2022 Q4 | 63.61 Million KRW | 182.34% |
| 2022 Q1 | 76.51 Million KRW | -94.14% |
| 2021 Q3 | 1.39 Billion KRW | -5.55% |
| 2021 FY | 1.3 Billion KRW | -20.58% |
| 2021 Q1 | 1.57 Billion KRW | -3.97% |
| 2021 Q2 | 1.47 Billion KRW | -6.4% |
| 2021 Q4 | 1.3 Billion KRW | -6.46% |
| 2020 FY | 1.64 Billion KRW | 44.87% |
| 2020 Q1 | 1.07 Billion KRW | -5.38% |
| 2020 Q2 | 1.16 Billion KRW | 8.31% |
| 2020 Q3 | 1.11 Billion KRW | -4.2% |
| 2020 Q4 | 1.64 Billion KRW | 47.56% |
| 2019 Q1 | 178.72 Million KRW | 0.0% |
| 2019 FY | 1.13 Billion KRW | 0.0% |
| 2019 Q4 | 1.13 Billion KRW | -4.27% |
| 2019 Q3 | 1.18 Billion KRW | -7.86% |
| 2019 Q2 | 1.28 Billion KRW | 619.52% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2012 Q1 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 Q2 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2011 Q2 | - KRW | 0.0% |
| 2011 Q1 | - KRW | 0.0% |
| 2011 Q3 | - KRW | 0.0% |
| 2011 FY | - KRW | 0.0% |
| 2011 Q4 | - KRW | 0.0% |
| 2010 Q3 | - KRW | 0.0% |
| 2010 Q2 | - KRW | 0.0% |
| 2010 Q4 | - KRW | 0.0% |
| 2010 Q1 | - KRW | 0.0% |
| 2010 FY | - KRW | 0.0% |
| 2009 Q3 | - KRW | 0.0% |
| 2009 FY | - KRW | 0.0% |
| 2009 Q2 | - KRW | 0.0% |
| 2009 Q1 | - KRW | 0.0% |
| 2009 Q4 | - KRW | 0.0% |
| 2008 Q2 | - KRW | -100.0% |
| 2008 Q3 | - KRW | 0.0% |
| 2008 Q4 | - KRW | 0.0% |
| 2008 FY | - KRW | -100.0% |
| 2008 Q1 | 29.45 Million KRW | -26.45% |
| 2007 Q3 | 50.46 Million KRW | -16.89% |
| 2007 Q4 | 40.04 Million KRW | -20.65% |
| 2007 FY | 40.04 Million KRW | 0.0% |
| 2007 Q1 | 70.82 Million KRW | 0.0% |
| 2007 Q2 | 60.72 Million KRW | -14.26% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 97.749% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.848% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 98.972% |
| HANDOK Inc. | 123.78 Billion KRW | 99.752% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | 35.458% |
| Yuhan Corporation | 60.23 Billion KRW | 99.49% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.81% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -201.574% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.626% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 47.984% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 94.925% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 98.342% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 97.56% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | 80.795% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 97.749% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -156.568% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.746% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 99.04% |
| JW Holdings Corporation | 20.65 Billion KRW | 98.514% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 97.929% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 98.976% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 98.976% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -40.233% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | 47.118% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 99.381% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 93.103% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 97.749% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 98.386% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.671% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 98.976% |
| Yuhan Corporation | 60.23 Billion KRW | 99.49% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 97.076% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 99.24% |
| Suheung Co., Ltd. | 74 Billion KRW | 99.585% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 98.976% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 92.631% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 97.199% |
| CKD Bio Corp. | 69.43 Billion KRW | 99.558% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 99.112% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 98.096% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -40.233% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.574% |
| Boryung Corporation | 151.7 Billion KRW | 99.798% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.609% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 94.925% |
| JW Lifescience Corporation | 168 Million KRW | -82.772% |